+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of K562 cells using TCF4 mouse mAb (green) and negative control (red).    

  
  

The TCF4 antibody targets the Transcription Factor 4 (TCF4), a member of the T-cell factor/lymphoid enhancer factor (TCF/LEF) family. TCF4 plays a critical role in the Wnt/β-catenin signaling pathway, where it binds to β-catenin to regulate the expression of genes involved in cell proliferation, differentiation, and development. Dysregulation of TCF4 is implicated in various cancers, including colorectal cancer, and neurological disorders such as schizophrenia and Pitt-Hopkins syndrome, a rare neurodevelopmental condition linked to TCF4 haploinsufficiency.

Antibodies against TCF4 are widely used in research to study its expression, localization, and function in both normal and diseased tissues. These tools enable detection of TCF4 isoforms, which arise from alternative splicing and contribute to its diverse roles in tissue-specific contexts. Applications include Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and chromatin immunoprecipitation (ChIP). Due to the structural complexity of TCF4 and overlapping epitopes with other TCF/LEF family members, antibody specificity is crucial for accurate experimental outcomes. Commercial TCF4 antibodies are typically validated in knockout models or siRNA-treated cells to confirm target selectivity. Research involving TCF4 antibodies continues to expand insights into its dual roles as an oncogene or tumor suppressor, depending on cellular context, and its potential as a therapeutic target.